Incb57643-103- A Phase 1, Open-Label, Safety And Tolerability Study Of Incb057643 In Participants With Myelofibrosis
Posted Date: Jan 18, 2021
- Investigator: Emily Curran
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy for participants with relapsed or refractory myelofibrosis. Safety will be measured by tracking the number of treatment emergent adverse events.
Criteria:
To Be Eligible: Must Have Relapsed Or Refractory Primary Myelofibrosis (Mf) Or Secondary Mfs (Post-Polycythemia Vera Mf, Post-Essential Thrombocythemia Mf), Must Not Be A Candidate For Potentially Curative Therapy, Including Hematopoietic Stem-Cell Transplantation, No Prior Receipt Of Any Bet Inhibitor, No Use Of Any Potent Cyp3a4 Inhibitors Or Inducers Within 14 Days, No History Of Bleeding Disorder
Keywords:
Myelofibrosis, Incb057643
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com